Detalles de la búsqueda
1.
Incidence of blast phase in myelofibrosis patients according to anemia severity at ruxolitinib start and during therapy.
Cancer
; 130(8): 1270-1280, 2024 Apr 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-38153814
2.
Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome.
Cancer
; 129(11): 1704-1713, 2023 06 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36932983
3.
Cancer Treatment Closer to the Patient Reduces Travel Burden, Time Toxicity, and Improves Patient Satisfaction, Results of 546 Consecutive Patients in a Northern Italian District.
Medicina (Kaunas)
; 59(12)2023 Dec 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-38138224
4.
Peripheral blasts are associated with responses to ruxolitinib and outcomes in patients with chronic-phase myelofibrosis.
Cancer
; 128(13): 2449-2454, 2022 07 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35363892
5.
Ruxolitinib rechallenge in resistant or intolerant patients with myelofibrosis: Frequency, therapeutic effects, and impact on outcome.
Cancer
; 127(15): 2657-2665, 2021 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33794557
6.
Second primary malignancy in myelofibrosis patients treated with ruxolitinib.
Br J Haematol
; 193(2): 356-368, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33222197
7.
Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis.
Cancer
; 126(6): 1243-1252, 2020 03 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-31860137
8.
Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real-world data.
Hematol Oncol
; 38(3): 372-380, 2020 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-32271957
9.
Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib.
Hematol Oncol
; 37(4): 418-423, 2019 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-30985017
10.
Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib.
Ann Hematol
; 98(4): 889-896, 2019 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-30515542
11.
Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients.
Br J Haematol
; 183(1): 35-46, 2018 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-30010187
12.
Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients.
Hematol Oncol
; 2018 Apr 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-29624703
13.
Correlation between Subpubic Arch Angle and Mode of Delivery in Large-for-Gestational-Age Fetuses.
Fetal Diagn Ther
; 44(3): 221-227, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-29232667
14.
Fetal head circumference and subpubic angle are independent risk factors for unplanned cesarean and operative delivery.
Acta Obstet Gynecol Scand
; 96(8): 1006-1011, 2017 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-28449356
15.
A Prognostic Model to Predict Ruxolitinib Discontinuation and Death in Patients with Myelofibrosis.
Cancers (Basel)
; 15(20)2023 Oct 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-37894394
16.
Reduction of phosphoinositide-phospholipase C beta1 methylation predicts the responsiveness to azacitidine in high-risk MDS.
Proc Natl Acad Sci U S A
; 106(39): 16811-6, 2009 Sep 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-19805378
17.
Characteristics and outcomes of five patients with COVID-19 and hematological malignancies.
Clin Case Rep
; 9(6): e04013, 2021 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-34136224
18.
[Territorial-based management of patients with cancer on active treatment following the Piacenza (north Italy) Model. Results of 4 consecutive years.] / Le cure oncologiche ed ematologiche sul territorio secondo il modello dell'ASL di Piacenza. Rendiconto di 4 anni consecutivi.
Recenti Prog Med
; 112(12): 785-791, 2021 12.
Artículo
en Italiano
| MEDLINE | ID: mdl-34924573
19.
The Akt/mammalian target of rapamycin signal transduction pathway is activated in high-risk myelodysplastic syndromes and influences cell survival and proliferation.
Cancer Res
; 67(9): 4287-94, 2007 May 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-17483341
20.
Determinants of Covid19 disease and of survival after Covid19 in MPN patients treated with ruxolitinib.
Blood Cancer J
; 13(1): 65, 2023 05 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-37137878